HYDERABAD, India--(BUSINESS WIRE)--GVK Biosciences, Asia’s leading Contract Research Organization, today announced that its Ahmedabad Clinical Pharmacology Unit successfully cleared the US FDA Audit with zero 483s/observations from the agency. USFDA visited and audited a First-to-File study for one of GVK BIO’s customers.
